Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
PLX4032/vemurafenib is a first-in-class small-molecule BRAFV600E inhibitor with clinical activity in patients with BRAF mutant melanoma. Nevertheless, drug resistance develops in treated patients, and strategies to overcome primary and acquired resistance are required. To explore the molecular mecha...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Elsevier
2011-12-01
|
| Rangatū: | Neoplasia: An International Journal for Oncology Research |
| Urunga tuihono: | http://www.sciencedirect.com/science/article/pii/S1476558611801004 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|